Pfizer vaccine rollout ‘formidable’ challenge
The largest scale vaccination campaign in UK history is about to begin.
But NHS leaders have warned that the vaccination programme for Covid-19 is a “marathon not a sprint”.
While the news of the approval of the Pfizer/BioNTech vaccine has been welcomed, health leaders have cautioned that the rollout of the vaccine poses a “formidable” challenge.
Meanwhile, scientists have hailed the vaccine approval as a “huge landmark in the global efforts to address this pandemic”.
Chris Hopson, chief executive of NHS Providers, said: “An effective vaccine, along with advances in treatment and rapid turnaround mass testing, presents real hope for a way out of the pandemic.
“It’s reassuring to know that the regulator has reached this decision only after very careful evaluation of safety, quality and effectiveness.
“The logistics of administering the Pfizer/BioNTech jab are formidable, but the NHS has been preparing for this, and trusts will play a key role.
“The health service has an excellent track record of delivering vaccination programmes – though this will be on an unprecedented scale, with added challenges because of the need to run mass vaccination centres and the requirement for cold storage.
“And while this announcement gives great cause for hope, it’s important to remember that this does not mean life gets back to normal – at least until the spring or early summer.
“For the time being our best defence against Covid-19 is to prevent infection by observing lockdown restrictions.
“We’ll need that to get through the tough winter weeks ahead.
“But now at least we have the prospect of better days ahead.”
Danny Mortimer, chief executive of the NHS Confederation, which represents organisations across the healthcare sector, added: “This is the starting klaxon for people readying to deliver the vaccine.
“What’s ahead will be a marathon and not a sprint, with many months ahead to vaccinate everyone who needs it.
“This welcome news, however, does not mean that we are immediately out of the woods.
“Our already-stretched NHS faces a monumental effort now to roll-out the vaccine quickly and effectively.”
He added: “What we cannot do now is let our guard down.
“The virus is still with us, is still dangerous and our health and social care sectors are under enormous pressure.
“It is crucial that everyone sticks to the rules and does what they can to control the stem of the virus this winter.”
Dame Donna Kinnair, chief executive and general secretary of the Royal College of Nursing said: “The news of the approval of this Covid-19 vaccine will come as a relief to many people in the UK.
“This will be a huge logistical operation and will require the services of those from across health services and beyond to make it work.
“As the plans for the roll-out are developed, nursing staff will continue to work with colleagues to ensure it can be safely delivered.
“It is essential these plans include details on maintaining day- to-day heath and care services for all those that need them.
Liam Smeeth, professor of clinical epidemiology at the London School of Hygiene and Tropical Medicine, said: “The continued progress on vaccines is fantastic news.
“A route towards a much better situation in the UK is becoming clear.
“A further circuit-breaker in January or possibly February is likely to be needed.
“But, it is realistic to hope that by March or April the vast majority of older people, care home residents, and those with severe conditions will have been immunised.
“We can then work towards wider immunisation – with ideally much of the population covered in time for next winter.
“Life won’t ever be the same as it was before Covid-19, but it will feel a whole lot better than now.
“For the foreseeable future, and maybe forever, we are very unlikely to reach the situation we are in with smallpox (gone), polio (almost gone), or measles (controlled in populations with high enough vaccine coverage).
“Instead, we are going to need to find ways to fairly happily live alongside this virus.”
Dr Michael Head, senior research fellow in global health at the University of Southampton, added: “This is excellent news and a huge landmark in the global efforts to address this pandemic.
“The regulators have clearly been satisfied with the data presented to them.
“The Pfizer vaccine does require storage at around -70C, which will pose significant logistical challenges for all countries that choose to use it.
“These are not insurmountable but certainly challenging.
“Other vaccines, such as the Oxford AstraZeneca candidate, require storage at much lesser temperatures and will be simpler to transport.
“Given we will certainly need more than one licensed vaccine to maximise global coverage, everyone will still be eagerly waiting for further developments from Oxford and Moderna.”